Royalty Pharma plc has grown revenue 2.4% a year over three years and 2.5% a year over five, with earnings per share compounding at 52%. Revenue growth, 3-year annual rate: +2.4% (Biotechnology median +21%). Revenue growth, 5-year rate: +2.5%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +52%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 8, FY2018 to FY2025, as filed.

RPRXRoyalty Pharma plc

HealthcareUSD

$61.80

$34.3752 weeks$62.08

Is it growing?

Is RPRX growing?

Royalty Pharma plc has grown revenue 2.4% a year over three years and 2.5% a year over five, with earnings per share compounding at 52%.

+2.4%

Revenue growth, 3-year annual rate · Biotechnology median +21% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +2.5%
Revenue growth, 5-year rate · +2.4% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +52%
Earnings per share, 3-year rate · revenue +2.4% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed